Peer-reviewed veterinary case report
Blood clotting problems in dogs with multicentric lymphoma
By Kol, A et al.·Published in Veterinary and comparative oncology·2015·Department of Pathology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serial haemostatic monitoring of dogs with multicentric lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with multicentric lymphoma (a type of cancer) were monitored for blood clotting issues during and after chemotherapy. Most of the dogs showed signs of hypercoagulability, meaning their blood was more likely to clot than normal, which can lead to serious complications. Even after treatment, many dogs continued to have these clotting problems for up to a month. Unfortunately, those with a faster rate of clot formation after finishing chemotherapy had shorter survival times. This highlights the importance of monitoring blood clotting in dogs undergoing treatment for lymphoma.
People also search for: dog lymphoma treatment · dog blood clotting issues · chemotherapy side effects in dogs · dog cancer survival rates
Abstract
Lymphoma is the most common haematopoietic malignancy in dogs and it has been associated with hypercoagulability and subsequent thromboembolism. The objectives of this study were to serially characterize the haemostatic status of dogs with multicentric lymphoma. Thromboelastography, thrombin-antithrombin complex concentration and routine haematology and coagulation panels were measured. Twenty-seven dogs were included in the study and 15 completed the study in remission. At presentation, 81% (22/27) of dogs with multicentric lymphoma had altered haemostatic profiles consistent with hypercoagulability. Laboratory evidence of hypercoagulability did not resolve during treatment or for up to 1 month following attainment of clinical remission. Accelerated rate of clot formation at the time of chemotherapeutic protocol completion was associated with decreased survival time. We concluded that dogs with multicentric lymphoma were frequently hypercoagulable from presentation through 4 weeks after the completion of chemotherapy. Increased angle and shortened K in dogs that have successfully completed their chemotherapeutic protocol may be associated with shorter survival times.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23710569/